To address this gap, we assessed the prognostic and predictive value of vitamin C in patients with stage IV CRC by comparing vitamin C level between cancer-free and cancer patients and analyzing the specific plasma vitamin C levels in RAS (NRAS/KRAS) and BRAF mutated CRC patients. Here, KRAS is linked to colorectal carcinoma.